Elacestrant

ORSERDU

Estrogen Receptor Antagonist

NADAC/unit N/A

No Shortage Tier 1: 35.9% PA Req: 198.8%

ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or....

Covered Lives

Generic Manufacturers

STEMLINE THERAPEUTICS INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Elacestrant drfinder.aiFind doctors who prescribe Elacestrant rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Elacestrant

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.